Reference:1. Arzerra® (ofatumumab) summary of product characteristics. West Sussex, UK; Novartis Europharm Limited; 2016.
The link you have chosen leads to a site maintained by a third party over whom Novartis has no control. As such, Novartis makes no representation as to the accuracy or any other aspect of the information on this site.
This is an international site for ARZERRA® (ofatumumab) and is intended for healthcare professionals outside the US.
ARZERRA® (ofatumumab) is approved in over 60 countries around the world.